Alum and a TLR7 agonist combined with built-in TLR4 and 5 agonists synergistically enhance immune responses against HPV RG1 epitope
Abstract To relieve the limitations of the human papillomavirus (HPV) vaccines based on L1 capsid protein, vaccine formulations based on RG1 epitope of HPV L2 using various built-in adjuvants are under study. Herein, we describe design and construction of a rejoined peptide (RP) harboring HPV16 RG1...
Main Authors: | Maryam Mashhadi Abolghasem Shirazi, Seyed Mehdi Sadat, Setareh Haghighat, Farzin Roohvand, Arash Arashkia |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-10-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-43965-3 |
Similar Items
-
Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine
by: Shi-Hao Zhou, et al.
Published: (2022-03-01) -
Deoxyguanosine is a TLR7 agonist
by: Davenne, T, et al.
Published: (2019) -
Comparison of human B cell activation by TLR7 and TLR9 agonists
by: Neys Lori, et al.
Published: (2008-07-01) -
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
by: Giorgio Frega, et al.
Published: (2020-01-01) -
Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells
by: Kuan-Yin Shen, et al.
Published: (2020-03-01)